Onyema Ogbuagu

• Albert Ko
• Anne Spichler Moffarah
• Brent A Moore
• Brett Lindenbach
• Craig B. Wilen
• Dana Dunne
• David Peaper
• E. Jennifer Edelman
• Faiza Yasin
• Frederick Lewis Altice
• Gerald Friedland
• Heidi J Zapata
• Janet Truebig
• Jeanette Tetrault
• Jessica Tuan
• John P Moriarty
• Lauren Pischel
• Laurie Andrews
• Lydia Aoun-Barakat
• Lynn Madden
• Maricar Malinis
• Marwan Mikheal Azar
• Merceditas Villanueva
• Michael Green
• Michael Virata
• Peiwen Lu
• Ritche Manos Hao
• Roland Assi
• Shaili Gupta
• Sheela Shenoi
• Shiv Gandhi
• Stephen Huot
• Tassos C. Kyriakides
• Wade Schulz
• Xuchen Zhang

Hepatitis C; HIV Infections; Coronavirus; Disk Diffusion Antimicrobial Tests; Health Care

Antimicrobial Resistance; Global Health; HIV/AIDS; e-Health

• Analyse en sous-groupe de l'efficacité du lénacapavir à la semaine 52 chez les PVVIH lourdement pré-traitésOgbuagu O, Segal-Maure S, DeJesus E, Avihingsanon A, Zurawski C, Osiyemi O, Crofoot G, Wang H, Dvory-Sobol H, Rhee M, Barrière G, Baeten J, Molina J. Analyse en sous-groupe de l'efficacité du lénacapavir à la semaine 52 chez les PVVIH lourdement pré-traités. Médecine Et Maladies Infectieuses Formation 2023, 2: s75. DOI: 10.1016/j.mmifmc.2023.03.186.
• Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)Tuan J, Sharma M, Kayani J, Davis M, McManus D, Topal J, Ogbuagu O. Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO). BMC Infectious Diseases 2023, 23: 258. PMID: 37101135, PMCID: PMC10130811, DOI: 10.1186/s12879-023-08198-9.
• Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment optionsTuan J, Ogbuagu O. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options. Expert Review Of Anti-infective Therapy 2023, 21: 565-570. PMID: 37067160, DOI: 10.1080/14787210.2023.2203913.
• Correction: HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief reportOgbuagu O, Sharma M, Igiraneza G, Andrews L, Tuan J, Barakat L. Correction: HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report. BMC Infectious Diseases 2023, 23: 224. PMID: 37046201, PMCID: PMC10100465, DOI: 10.1186/s12879-023-08159-2.
• HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief reportOgbuagu O, Sharma M, Igiraneza G, Andrews L, Tuan J, Barakat L. HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report. BMC Infectious Diseases 2023, 23: 146. PMID: 36890468, PMCID: PMC9993362, DOI: 10.1186/s12879-023-08075-5.
• Acute kidney injury due to myoglobin cast nephropathy in the setting of coronavirus disease 2019-mediated rhabdomyolysis: a case reportTuan J, Ogbuagu O, Kumar D, Altice F, Fikrig M. Acute kidney injury due to myoglobin cast nephropathy in the setting of coronavirus disease 2019-mediated rhabdomyolysis: a case report. Journal Of Medical Case Reports 2022, 16: 491. PMID: 36578087, PMCID: PMC9795945, DOI: 10.1186/s13256-022-03721-z.
• LB1577. Outcomes of Pregnant Women Exposed to Sotrovimab for the Treatment of COVID-19 in the Omicron Predominant Era (PRESTO)Tuan J, Sharma M, Kayani J, Davis M, McManus D, Topal J, Ogbuagu O. LB1577. Outcomes of Pregnant Women Exposed to Sotrovimab for the Treatment of COVID-19 in the Omicron Predominant Era (PRESTO). Open Forum Infectious Diseases 2022, 9: ofac492.1887. PMCID: PMC9752459, DOI: 10.1093/ofid/ofac492.1887.
• 1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 resultsOgbuagu O, Segal-Maurer S, Ratanasuwan W, Trottier B, Brunetta J, Shirasaka T, Koenig E, Wang H, Margot N, Dvory-Sobol H, Rhee M, Baeten J, Molina J. 1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results. Open Forum Infectious Diseases 2022, 9: ofac492.108. PMCID: PMC9752342, DOI: 10.1093/ofid/ofac492.108.
• Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)Tuan JJ, Zapata H, Barakat L, Andrews L, Behnegar A, Kim YW, Kayani J, Mutic S, Ryall L, Turcotte B, Critch-Gilfillan T, Zhao M, Salahuddin S, Gupta S, Sutton R, Friedland G, Emu B, Ogbuagu O. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH). BMC Infectious Diseases 2022, 22: 744. PMID: 36131232, PMCID: PMC9491266, DOI: 10.1186/s12879-022-07737-0.
• Early infant diagnosis of HIV infection at the John F. Kennedy Medical Center, Monrovia, LiberiaI U U, Adeiza M, Ideh R, Ogbuagu O. Early infant diagnosis of HIV infection at the John F. Kennedy Medical Center, Monrovia, Liberia. HIV Research & Clinical Practice 2022, 23: 136-140. PMID: 35703420, DOI: 10.1080/25787489.2022.2086093.
• Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)Cespedes M, Das M, Hojilla JC, Blumenthal J, Mounzer K, Ramgopal M, Hodge T, Torres TS, Peterson C, Shibase S, Elliott A, Demidont AC, Callaghan L, Watson CC, Carter C, Kintu A, Baeten JM, Ogbuagu O. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). PLOS ONE 2022, 17: e0267780. PMID: 35657826, PMCID: PMC9165827, DOI: 10.1371/journal.pone.0267780.
• De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case reportGandhi S, Klein J, Robertson AJ, Peña-Hernández MA, Lin MJ, Roychoudhury P, Lu P, Fournier J, Ferguson D, Mohamed Bakhash SAK, Catherine Muenker M, Srivathsan A, Wunder EA, Kerantzas N, Wang W, Lindenbach B, Pyle A, Wilen CB, Ogbuagu O, Greninger AL, Iwasaki A, Schulz WL, Ko AI. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nature Communications 2022, 13: 1547. PMID: 35301314, PMCID: PMC8930970, DOI: 10.1038/s41467-022-29104-y.
• Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre studySridhar S, Joaquin A, Bonaparte MI, Bueso A, Chabanon AL, Chen A, Chicz RM, Diemert D, Essink BJ, Fu B, Grunenberg NA, Janosczyk H, Keefer MC, Rivera M DM, Meng Y, Michael NL, Munsiff SS, Ogbuagu O, Raabe VN, Severance R, Rivas E, Romanyak N, Rouphael NG, Schuerman L, Sher LD, Walsh SR, White J, von Barbier D, de Bruyn G, Canter R, Grillet MH, Keshtkar-Jahromi M, Koutsoukos M, Lopez D, Masotti R, Mendoza S, Moreau C, Ceregido MA, Ramirez S, Said A, Tavares-Da-Silva F, Shi J, Tong T, Treanor J, Diazgranados CA, Savarino S. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. The Lancet Infectious Diseases 2022, 22: 636-648. PMID: 35090638, PMCID: PMC8789245, DOI: 10.1016/s1473-3099(21)00764-7.
• Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report)Adeiza M, Kekulah I, Wachekwa I, Ogbuagu O. Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report). PAMJ Clinical Medicine 2022, 8 DOI: 10.11604/pamj-cm.2022.8.47.33930.
• 848. Approaches to Optimize Recruitment of Historically Underrepresented Black and Hispanic/LatinX MSM, Transgender, and Gender Non-binary Individuals into the Lenacapavir for PrEP (PURPOSE 2) TrialCespedes M, Blumenthal J, Mounzer K, Ramgopal M, Hodge T, Elliott A, Demidont A, Watson C, Carter C, Kintu A, Das M, Baeten J, Ogbuagu O. 848. Approaches to Optimize Recruitment of Historically Underrepresented Black and Hispanic/LatinX MSM, Transgender, and Gender Non-binary Individuals into the Lenacapavir for PrEP (PURPOSE 2) Trial. Open Forum Infectious Diseases 2021, 8: 514-514. PMCID: PMC8643746, DOI: 10.1093/ofid/ofab466.1043.
• High HIV Detection in a Tertiary Facility in Liberia: Implications and OpportunitiesOgbuagu O, Wachekwa I, Yasin F, Nuta C, Donato S, Toomey J, Adeiza M, Barakat LA. High HIV Detection in a Tertiary Facility in Liberia: Implications and Opportunities. Annals Of Global Health 2021, 87: 117. PMID: 34900617, PMCID: PMC8622250, DOI: 10.5334/aogh.3243.
• Gaps and Opportunities in HIV Service Delivery in High Volume HIV Care Centers in Liberia: Lessons From the FieldAdeiza MA, Wachekwa I, Nuta C, Donato S, Koomson F, Whitney J, Plyler C, Kerr L, Sackey G, Dunbar E, Talbert-Slagle K, Klar R, Marsh RH, Caldwell S, Toomey J, Ogbuagu O. Gaps and Opportunities in HIV Service Delivery in High Volume HIV Care Centers in Liberia: Lessons From the Field. Annals Of Global Health 2021, 87: 115. PMID: 34900615, PMCID: PMC8622325, DOI: 10.5334/aogh.3246.
• Qualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIVTuan JJ, Zapata H, Critch‐Gilfillan T, Ryall L, Turcotte B, Mutic S, Andrews L, Roh ME, Friedland G, Barakat L, Ogbuagu O. Qualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIV. HIV Medicine 2021, 23: 178-185. PMID: 34632695, PMCID: PMC8652674, DOI: 10.1111/hiv.13188.
• Facing COVID-19 in Liberia: Adaptations of the Resilient and Responsive Health Systems InitiativeMarsh RH, Plyler C, Miller M, Klar R, Adeiza M, Wachekwa I, Koomson F, Garlo JL, Kruah K, Lake SC, Matte R, Cook R, Maweu D, Kerr L, Ogbuagu O, Talbert-Slagle K, Dahn B. Facing COVID-19 in Liberia: Adaptations of the Resilient and Responsive Health Systems Initiative. Annals Of Global Health 2021, 87: 101. PMID: 34707981, PMCID: PMC8499715, DOI: 10.5334/aogh.3245.
• Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, Swanson KA, Ma H, Xu X, Koury K, Kalina WV, Cooper D, Jennings T, Brandon DM, Thomas SJ, Türeci Ö, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group.. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med 2021, 385:239-250.
• Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOgbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD, team D, Antinori A, Apea V, Asmuth D, Avery A, Benson P, Bergin C, Berhe M, Brar I, Brinson C, Brunetta J, Burack J, Campbell T, Cespedes M, Clarke A, Coleman M, Coll J, Casal M, Creticos C, Crofoot G, Cruickshank F, Cua E, Daar E, de Wet J, DeJesus E, Del Romero Guerrero J, Dinges W, Doblecki-Lewis S, Donovan T, Dosekun O, Flamm J, Gallant J, Gerstoft J, Gilson R, Gladstein J, Grant R, Grossberg R, Haas B, Halperin J, Hardy W, Hare C, Hassler S, Hengel R, Henry W, Hodge T, Hosek S, Hurt C, Iandiorio M, Jessen H, Kegg S, Knecht G, Kronborg G, Krznaric I, LaMarca A, Larsen C, Larsen O, Lazzarin A, Leen C, Lucasti C, Mallon P, Mannheimer S, Markowitz M, Martorell C, Mayer K, Mills A, Molina J, Morris S, Mounzer K, Nwokolo N, Ogbuagu O, Osiyemi O, Petroll A, Philibert P, Phoenix J, Pialoux G, Podzamczer D, Post F, Prins M, Ramgopal M, Rashbaum B, Reeves I, Richmond G, Rieger A, Ruane P, Salazar L, Scarsella A, Schembri G, Scott M, Shalit P, Sinclair G, Sobieszczyk M, Spinner C, Stephens J, Szabo J, Taylor S, Thompson M, Tremblay C, Trottier B, Voskuhl G, Wade B, Wohl D, Workowski K, Yawetz S, Young B. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet HIV 2021, 8: e397-e407. PMID: 34197772, DOI: 10.1016/s2352-3018(21)00071-0.
• Late neurosyphilis and VZV meningoencephalitis coinfectionCarr K, Ogbuagu O. Late neurosyphilis and VZV meningoencephalitis coinfection. BMJ Case Reports 2021, 14: e240412. PMID: 34162599, PMCID: PMC8231027, DOI: 10.1136/bcr-2020-240412.
• Race and ethnicity do not impact eligibility for remdesivir: A single-center experiencePischel L, Walelo M, Benson J, Osborn R, Schrier R, Tuan J, Barakat L, Ogbuagu O. Race and ethnicity do not impact eligibility for remdesivir: A single-center experience. PLOS ONE 2021, 16: e0250735. PMID: 33956849, PMCID: PMC8101938, DOI: 10.1371/journal.pone.0250735.
• A new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding?Tuan J, Spichler-Moffarah A, Ogbuagu O. A new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding? BMJ Case Reports 2021, 14: e240531. PMID: 33542020, PMCID: PMC8098910, DOI: 10.1136/bcr-2020-240531.
• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020, 383:2603-2615.
• Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19Spinner CD, Gottlieb RL, Criner GJ, López J, Cattelan AM, Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19. JAMA 2020, 324: 1048-1057. PMID: 32821939, PMCID: PMC7442954, DOI: 10.1001/jama.2020.16349.
• Transmission risk of respiratory viruses in natural and mechanical ventilation environments: implications for SARS-CoV-2 transmission in AfricaSopeyin A, Hornsey E, Okwor T, Alimi Y, Raji T, Mohammed A, Moges H, Onwuekwe EVC, Minja FJ, Gon G, Ogbuagu O, Ogunsola F, Paintsil E. Transmission risk of respiratory viruses in natural and mechanical ventilation environments: implications for SARS-CoV-2 transmission in Africa. BMJ Global Health 2020, 5: e003522. PMID: 32863269, PMCID: PMC7462043, DOI: 10.1136/bmjgh-2020-003522.
• 1328. Post-War and Post-Ebola HIV Care Continuum in a Liberian Academic Center: Fresh Insights and Trends Over 5-Year PeriodWatchekwa I, Ogbuagu O, Donato S, Nuta C, Barakat L. 1328. Post-War and Post-Ebola HIV Care Continuum in a Liberian Academic Center: Fresh Insights and Trends Over 5-Year Period. Open Forum Infectious Diseases 2019, 6: s480-s480. PMCID: PMC6808810, DOI: 10.1093/ofid/ofz360.1189.
• 1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER TrialMills A, Workowski K, Campbell T, Benson P, Crofoot G, Salazar L, Ogbuagu O, Shalit P, Trottier B, Carter C, Wong P, Brainard D, McCallister S, Das M, Doblecki-Lewis S. 1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial. Open Forum Infectious Diseases 2019, 6: s64-s64. PMCID: PMC6808931, DOI: 10.1093/ofid/ofz359.139.
• 1261. Alarming High Rate of HIV Detected by Testing and Prevention Opportunities: Observations From the Largest HIV Program in LiberiaOgbuagu O, Watchekwa I, Donato S, Nuta C, Barakat L. 1261. Alarming High Rate of HIV Detected by Testing and Prevention Opportunities: Observations From the Largest HIV Program in Liberia. Open Forum Infectious Diseases 2019, 6: s454-s454. PMCID: PMC6809135, DOI: 10.1093/ofid/ofz360.1124.
• Preferences for implementation of HIV pre-exposure prophylaxis (PrEP): Results from a survey of primary care providersEdelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham CO, Ogbuagu O, Patel VV, Phillips KA, Tetrault JM, Shah M, Blackstock O. Preferences for implementation of HIV pre-exposure prophylaxis (PrEP): Results from a survey of primary care providers. Preventive Medicine Reports 2019, 17: 101012. PMID: 31890474, PMCID: PMC6926349, DOI: 10.1016/j.pmedr.2019.101012.
• Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patientsMaughan A, Sadigh K, Angulo-Diaz V, Mandimika C, Villanueva M, Lim JK, Ogbuagu O. Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients. BMC Infectious Diseases 2019, 19: 378. PMID: 31053098, PMCID: PMC6500032, DOI: 10.1186/s12879-019-3974-7.
• Correction: Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in RwandaKambutse I, Igiraneza G, Shenoi S, Ogbuagu O. Correction: Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda. PLOS ONE 2019, 14: e0212933. PMID: 30794678, PMCID: PMC6386218, DOI: 10.1371/journal.pone.0212933.
• 2234. Implementing a Co-located HCV Clinic Within an HIV Clinic: Four Year ExperienceVillanueva M, Rizk C, Shiferaw B, Ogbuagu O, Malinis M, Miceli J. 2234. Implementing a Co-located HCV Clinic Within an HIV Clinic: Four Year Experience. Open Forum Infectious Diseases 2018, 5: s660-s661. PMCID: PMC6252933, DOI: 10.1093/ofid/ofy210.1887.
• 599. Expanding HIV Training in Internal Medicine Residency Program: A Prospect to Meet the HIV Workforce DemandBarakat L, Dunne D, Ogbuagu O, Green M. 599. Expanding HIV Training in Internal Medicine Residency Program: A Prospect to Meet the HIV Workforce Demand. Open Forum Infectious Diseases 2018, 5: s219-s220. PMCID: PMC6253729, DOI: 10.1093/ofid/ofy210.606.
• Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in RwandaKambutse I, Igiraneza G, Ogbuagu O. Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda. PLOS ONE 2018, 13: e0207650. PMID: 30475841, PMCID: PMC6261021, DOI: 10.1371/journal.pone.0207650.
• The Changing Face of HIV CareBarakat LA, Dunne DW, Tetrault JM, Soares S, Chia D, Ogbuagu OE, Moriarty JP, Huot SJ, Green ML. The Changing Face of HIV Care. Academic Medicine 2018, 93: 1673-1678. PMID: 29901657, DOI: 10.1097/acm.0000000000002317.
• Dolutegravir/rilpivirine for the treatment of HIV-1 infectionDowers E, Zamora F, Barakat LA, Ogbuagu O. Dolutegravir/rilpivirine for the treatment of HIV-1 infection. HIV/AIDS - Research And Palliative Care 2018, 10: 215-224. PMID: 30464642, PMCID: PMC6220428, DOI: 10.2147/hiv.s157855.
• Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical settingJacobson K, Ogbuagu O. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting. Medicine 2018, 97: e13016. PMID: 30412140, PMCID: PMC6221636, DOI: 10.1097/md.0000000000013016.
• Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical SettingsOgbuagu O, Marshall BDL, Tiberio P, Ogunbajo A, Barakat L, Montgomery M, Almonte A, Wray T, Williams EC, Edelman EJ, Chan PA. Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings. AIDS And Behavior 2018, 23: 190-200. PMID: 30145707, PMCID: PMC7020905, DOI: 10.1007/s10461-018-2260-9.
• Infections in HIV-Infected PatientsOgbuagu O, Bruce R. Infections in HIV-Infected Patients. 2018, 243-281. DOI: 10.1007/978-3-319-77674-3_13.
• HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice systemRutledge R, Madden L, Ogbuagu O, Meyer JP. HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. AIDS Care 2018, 30: 1282-1289. PMID: 29527934, PMCID: PMC6085161, DOI: 10.1080/09540121.2018.1447079.
• The Natural History and Predictors of Liver Fibrosis Progression Using the FIB-4 Score Among HIV/HCV Co-infected Adults in an Outpatient Clinic in the USAYuh B, Kyriakides T, Ogbuagu O, Villanueva M. The Natural History and Predictors of Liver Fibrosis Progression Using the FIB-4 Score Among HIV/HCV Co-infected Adults in an Outpatient Clinic in the USA. Open Forum Infectious Diseases 2017, 4: s658-s659. DOI: 10.1093/ofid/ofx163.1753.
• Comparison of Time to Viral Suppression Among Treatment-Naïve HIV-Infected Adults Initiating Combination Antiretroviral Therapy by Antiretroviral Regimen ClassJacobson K, Ogbuagu O. Comparison of Time to Viral Suppression Among Treatment-Naïve HIV-Infected Adults Initiating Combination Antiretroviral Therapy by Antiretroviral Regimen Class. Open Forum Infectious Diseases 2017, 4: s432-s432. PMCID: PMC5630773, DOI: 10.1093/ofid/ofx163.1090.
• Five-Year Antimicrobial Susceptibility Trends Among Bacterial Isolates from King Faisal Hospital Tertiary Health-Care Facility in Kigali, RwandaCarroll M, Rangaiahagari A, Musabeyezu E, Singer D, Ogbuagu O. Five-Year Antimicrobial Susceptibility Trends Among Bacterial Isolates from King Faisal Hospital Tertiary Health-Care Facility in Kigali, Rwanda. Clinical Therapeutics 2017, 39: e4-e5. DOI: 10.1016/j.clinthera.2017.05.017.
• Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patientsOgbuagu O, Hao R, Virata M, Villanueva M, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2017, 6: 620. DOI: 10.12688/f1000research.11397.1.
• Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendationsKoff A, Goldberg C, Ogbuagu O. Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations. Annals Of Medicine 2017, 49: 534-544. PMID: 28409656, DOI: 10.1080/07853890.2017.1320423.
• Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patientsOgbuagu O. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert Review Of Anti-infective Therapy 2016, 14: 1113-1126. PMID: 27797606, DOI: 10.1080/14787210.2016.1255551.
• Five-Year Antimicrobial Susceptibility Trends Among Bacterial Isolates from a Tertiary Health-Care Facility in Kigali, Rwanda.Carroll M, Rangaiahagari A, Musabeyezu E, Singer D, Ogbuagu O. Five-Year Antimicrobial Susceptibility Trends Among Bacterial Isolates from a Tertiary Health-Care Facility in Kigali, Rwanda. American Journal Of Tropical Medicine And Hygiene 2016, 95: 1277-1283. PMID: 27799637, PMCID: PMC5154439, DOI: 10.4269/ajtmh.16-0392.
• The Natural History of FIB-4 Score Progression Among HIV/Hepatitis C Virus (HCV)–Coinfected Adults in an Outpatient ClinicYuh B, Ogbuagu O, Villanueva M. The Natural History of FIB-4 Score Progression Among HIV/Hepatitis C Virus (HCV)–Coinfected Adults in an Outpatient Clinic. Open Forum Infectious Diseases 2016, 3: 2147. DOI: 10.1093/ofid/ofw172.1695.
• Histoplasmosis in a Nonendemic Area: An Often Unrecognized DiseaseAzar M, Assi R, Ogbuagu O, Peaper D, Zhang X, Hage C, Wheat L, Malinis M. Histoplasmosis in a Nonendemic Area: An Often Unrecognized Disease. Open Forum Infectious Diseases 2016, 3: 1614. DOI: 10.1093/ofid/ofw172.1314.
• A Matched Case-Control Study of Clinical Outcomes of Patients With Daptomycin Non-Susceptible and Daptomycin Susceptible Vancomycin-Resistant Enterococcal BacteremiaSack J, Malinis M, Ogbuagu O. A Matched Case-Control Study of Clinical Outcomes of Patients With Daptomycin Non-Susceptible and Daptomycin Susceptible Vancomycin-Resistant Enterococcal Bacteremia. Open Forum Infectious Diseases 2016, 3: 1064. DOI: 10.1093/ofid/ofw172.767.
• Establishment of a hospital-acquired infection surveillance system in a teaching hospital in RwandaLukas S, Hogan U, Muhirwa V, Davis C, Nyiligira J, Ogbuagu O, Wong R. Establishment of a hospital-acquired infection surveillance system in a teaching hospital in Rwanda. International Journal Of Infection Control 2016, 12 DOI: 10.3396/ijic.v12i3.018.16.
• Unusual presentation of disseminated Nocardia abscessus infection in a patient with AIDSSherbuk J, Saly D, Barakat L, Ogbuagu O. Unusual presentation of disseminated Nocardia abscessus infection in a patient with AIDS. BMJ Case Reports 2016, 2016: bcr2016215649. PMID: 27440848, PMCID: PMC4964189, DOI: 10.1136/bcr-2016-215649.
• Steroid-exacerbated HIV-associated cutaneous Kaposi’s sarcoma immune reconstitution inflammatory syndrome: ‘Where a good intention turns bad’Chabria S, Barakat L, Ogbuagu O. Steroid-exacerbated HIV-associated cutaneous Kaposi’s sarcoma immune reconstitution inflammatory syndrome: ‘Where a good intention turns bad’. International Journal Of STD & AIDS 2016, 27: 1026-1029. PMID: 26769754, DOI: 10.1177/0956462415627735.
• Drug interactions between buprenorphine, methadone and hepatitis C therapeuticsOgbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion On Drug Metabolism & Toxicology 2016, 12: 721-731. PMID: 27140427, DOI: 10.1080/17425255.2016.1183644.
• Predictors of Mortality From Sepsis Smong an African Patient Cohort: A Prospective Study From Two Tertiary Healthcare Facilities in Kigali, Rwanda.Sugira V, Simpao M, Ogbuagu O, Walker T. Predictors of Mortality From Sepsis Smong an African Patient Cohort: A Prospective Study From Two Tertiary Healthcare Facilities in Kigali, Rwanda. Open Forum Infectious Diseases 2015, 2: 821. DOI: 10.1093/ofid/ofv133.538.
• Trends in Tuberculosis Cases at a Connecticut Hospital, 2005–2014Yuh T, Ogbuagu O, Villanueva M, Shenoi S. Trends in Tuberculosis Cases at a Connecticut Hospital, 2005–2014. Open Forum Infectious Diseases 2015, 2: 566. DOI: 10.1093/ofid/ofv133.440.
• Su1395 Eligibility of a Real World Population for Phase 3 Clinical Trials for Chronic Hepatitis C InfectionAngulo-Diaz V, Sadigh K, Ogbuagu O, Sarkar S, Villanueva M, Lim J. Su1395 Eligibility of a Real World Population for Phase 3 Clinical Trials for Chronic Hepatitis C Infection. Gastroenterology 2015, 148: s-496-s-497. DOI: 10.1016/s0016-5085(15)31666-8.
• CD8 T-Cell Lymphocytosis and Associated Clinical Syndromes in HIV-Infected Patients.Tiberio PJ, Ogbuagu OE. CD8 T-Cell Lymphocytosis and Associated Clinical Syndromes in HIV-Infected Patients. Aids Reviews 2015, 17: 202-11. PMID: 26679852.
• 1558Clinico-demographic Profile and Treatment Outcomes of Pediatric Participants of a Large Outpatient HIV Clinic in Kigali, RwandaRubagumya F, Nshogoza G, Nkurikiyimfura J, Manzi O, Ogbuagu O. 1558Clinico-demographic Profile and Treatment Outcomes of Pediatric Participants of a Large Outpatient HIV Clinic in Kigali, Rwanda. Open Forum Infectious Diseases 2014, 1: s414-s415. PMCID: PMC5782197, DOI: 10.1093/ofid/ofu052.1104.
• Single-pill regimens for HIV-1 infection.Ogbuagu O, Ogbuagu A. Single-pill regimens for HIV-1 infection. New England Journal Of Medicine 2014, 371: 1844. PMID: 25372100, DOI: 10.1056/nejmc1410930.
• SEQUENTIAL LOW COST INTERVENTIONS DOUBLE HAND HYGIENE RATES AMONG MEDICAL TEAMS IN A RESOURCE LIMITED SETTING. RESULTS OF A HAND HYGIENE QUALITY IMPROVEMENT PROJECT CONDUCTED AT UNIVERSITY TEACHING HOSPITAL OF KIGALI (CHUK), KIGALI, RWANDA.Manzi O, Ogbuagu O. SEQUENTIAL LOW COST INTERVENTIONS DOUBLE HAND HYGIENE RATES AMONG MEDICAL TEAMS IN A RESOURCE LIMITED SETTING. RESULTS OF A HAND HYGIENE QUALITY IMPROVEMENT PROJECT CONDUCTED AT UNIVERSITY TEACHING HOSPITAL OF KIGALI (CHUK), KIGALI, RWANDA. East African Medical Journal 2014, 91: 44-9. PMID: 26859019.
• 216: Unique Etiology of Hypercalcemia in Male to Female Transgender PatientsOgbuagu O, Soltani P, Lawrence K, Stern A. 216: Unique Etiology of Hypercalcemia in Male to Female Transgender Patients. American Journal Of Kidney Diseases 2010, 55: b85. DOI: 10.1053/j.ajkd.2010.02.223.